Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Revolution Medicines (RVMD) over the last 5 years, with Dec 2024 value amounting to $167.7 million.

  • Revolution Medicines' Shares Outstanding (Diluted Average) rose 13.42% to $189.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.2 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of $167.7 million for FY2024, which is 48.24% up from last year.
  • According to the latest figures from FY2024, Revolution Medicines' Shares Outstanding (Diluted Average) is $167.7 million, which was up 48.24% from $113.1 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Diluted Average) peaked at $167.7 million during FY2024, and registered a low of $54.9 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $120.5 million, with a median of $113.1 million in 2023.
  • Data for Revolution Medicines' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 48.24% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Revolution Medicines' Shares Outstanding (Diluted Average) stood at $54.9 million in 2020, then soared by 32.68% to $72.8 million in 2021, then grew by 10.74% to $80.6 million in 2022, then skyrocketed by 40.34% to $113.1 million in 2023, then spiked by 48.24% to $167.7 million in 2024.